Back to top

cell-therapy: Archive

Zacks Equity Research

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.

VRTXNegative Net Change ADMAPositive Net Change FGENPositive Net Change ANVSPositive Net Change

Zacks Equity Research

Waters (WAT) Boosts Waters Operating Segment With HPLC System

Waters (WAT) launches Alliance iS Bio HPLC system to improve efficiency across biopharma QC laboratories, boosting its Waters Operating segment.

WATPositive Net Change APositive Net Change TMOPositive Net Change BIOPositive Net Change

Zacks Equity Research

New Strong Buy Stocks for April 2nd

CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.

SIGAPositive Net Change CPGPositive Net Change CXDONegative Net Change HITINo Net Change CTKBPositive Net Change

Zacks Equity Research

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

GSKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ALLOPositive Net Change